grant
Immuno/Oncology (IO)
NIHUS FederalResearch GrantFY202570-kD Heat-Shock ProteinAbbreviationsAcidsAcute GVHDAcute Graft Versus Host DiseaseAcute PoliomyelitisAddressAdoptive Cell TransfersAmericanAntibodiesAntineoplastic VaccineAttenuatedAutomobile DrivingAwardB blood cellsB cellB cellsB-Cell ActivationB-CellsB-LymphocytesB-cellB7-H1Basic ResearchBasic ScienceBeta Cadherin-Associated ProteinBeta-1 CateninBindingBioinformaticsBiometricsBiometryBiostatisticsBlood Plasma CellBlood monocyteBreastCAR T cellsCAR modified T cellsCAR-TCAR-TsCCSGCD150CD150 antigenCD154 AntigensCD274CD40 LigandCD40-LCD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCDw150 proteinCRISPR editing screenCRISPR screenCRISPR-based screenCRISPR/Cas9 screenCUL-2Ca(2+)-Calmodulin Dependent Protein KinaseCaMKCalcium/calmodulin-dependent protein kinaseCalmodulin-Dependent Protein KinasesCalmodulin-KinaseCancer BiologyCancer CenterCancer Center Support GrantCancer PatientCancer VaccinesCancersCaringCatchment AreaCell BodyCell Communication and SignalingCell FunctionCell PhysiologyCell ProcessCell SignalingCell TherapyCellsCellular FunctionCellular PhysiologyCellular ProcessCheckpoint inhibitorChronicChronic GVHDClinical ResearchClinical StudyClinical TrialsCollaborationsColorectal NeoplasmsColorectal TumorsCommunitiesCommunity OutreachComplement Factor HCyclic GMPCytotoxic cellDendritic CellsDetectionDevelopmentDiseaseDisorderDysfunctionEducation and TrainingEndogenous Interferon BetaEngineeringEnrollmentEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessFactor HFamily memberFibroblast InterferonFosteringFunctional disorderFundingFutureGene ExpressionGene TranscriptionGenesGenetic TranscriptionGenomicsGlioblastomaGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaGuanosine Cyclic MonophosphateGvHDHIGM1HSP 70HSP70Heat-Shock Proteins 70Hematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematopoietic CancerHomologous Wasting DiseaseHumanIFN-βIFNbIMD3ImageImmuneImmune EvasionImmune MonitoringImmune ToleranceImmune checkpoint inhibitorImmune mediated therapyImmunesImmunityImmunochemical ImmunologicImmunologicImmunologic MonitoringImmunologic ToleranceImmunologicalImmunological MonitoringImmunologicallyImmunologically Directed TherapyImmunologicsImmunomodulationImmunomonitoringImmunooncologyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapeutic agentImmunotherapyInfiltrationInflammasomeInflammationInterdisciplinary ResearchInterdisciplinary StudyInterferon-βIntervention TrialInterventional trialIntracellular Communication and SignalingInvestigatorsK lymphocyteKeytrudaLarge Bowel TumorLarge Intestine NeoplasmLarge Intestine TumorMacrophageMalignant Hematologic NeoplasmMalignant MelanomaMalignant NeoplasmsMalignant TumorMalignant Tumor of the LungMalignant neoplasm of lungMarrow monocyteMelanomaMicrofluidic DeviceMicrofluidic Lab-On-A-ChipMicrofluidic MicrochipsMitochondriaModern ManMolecularMolecular InteractionMultidisciplinary CollaborationMultidisciplinary ResearchMφNK CellsNSCLCNSCLC - Non-Small Cell Lung CancerNatural Interferon BetaNatural Killer CellsNatural human interferon betaNeoplasm VaccinesNerve Transmitter SubstancesNeurotransmittersNon-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaNucleic Acid BindingOligosaccharidesOncologyOncology CancerOncolytic virusesPD 1PD-1PD-1 antibodyPD-L1PD1PD1 antibodyPDL-1PRO2286PaperParticipantPathologyPathway interactionsPatientsPeer ReviewPhenotypePhysiopathologyPlasma CellsPlasmacytesPolioPoliomyelitisPolymersPreclinical TestingProcessProductionProductivityProgenitor Cell TransplantationProgrammed Cell Death 1 Ligand 1Programmed Death Ligand 1ProteinsPublishingPulmonary CancerPulmonary malignant NeoplasmR-Series Research ProjectsR01 MechanismR01 ProgramRNA ExpressionRNA replicationRNA vaccineRNA-based vaccineRadiation OncologyReceptor SignalingRecombinantsRecurrenceRecurrentRefractoryResearchResearch ActivityResearch GrantsResearch PersonnelResearch Project GrantsResearch ProjectsResearch ResourcesResearch SupportResearchersResistanceResourcesRhinovirusRoleRunt DiseaseSLAM proteinSYKSYK geneSchoolsScienceScientistSeriesServicesSignal TransductionSignal Transduction SystemsSignalingSiteSocietiesSolidSpleen Tyrosine KinaseStem Cell TransplantationStem cell transplantStromal CellsSubcellular ProcessT cell responseT cells for CART-B Cell Activating MoleculeT-Cell gp39 AntigenT-CellsT-LymphocyteT8 CellsT8 LymphocytesTNF-Related Activation ProteinTestingTherapeuticTherapy trialToxic effectToxicitiesTraining and EducationTranscriptionTranslational ResearchTranslational ScienceTranslationsTumor CellTumor ExpansionTumor Necrosis Factor Ligand Superfamily Member 5Tumor VaccinesTumor-Infiltrating LymphocytesTyrosine-Protein Kinase SYKUnderrepresented GroupsUnderrepresented PopulationsUniversitiesVaccinesVeiled CellsViralVirusWorkaPD-1aPD1activated B cellsacute graft vs host diseaseacute graft vs. host diseaseadoptive cell therapyadoptive cellular therapyanti programmed cell death 1anti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 monoclonal antibodiesanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 monoclonal antibodiesanti-canceranti-cancer immunotherapyanti-cancer researchanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed death-1 antibodyanti-tumor immune responseanti-tumor vaccineantiPD-1anticancer immunotherapyantigen bindingantigen boundattenuateattenuatesbeta catbeta cateninbiobankbiological signal transductionbiorepositorycGMPcalcium-calmodulin-dependent PKcalcium-calmodulin-dependent PK type IIcalmodulin dependent protein kinasecancer clinical trialcancer immune therapeuticscancer immunobiologycancer immunotherapeuticscancer immunotherapycancer infiltrating T cellscancer microenvironmentcancer researchcancer riskcell based interventioncell mediated interventioncell mediated therapiescell-based therapeuticcell-based therapycellular therapeuticcellular therapychimeric antigen T cell receptorchimeric antigen receptorchimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cellschimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellschronic graft versus host diseasechronic graft vs host diseasechronic graft vs. host diseaseclinical investigationclinical translationclinically translatableclustered regularly interspaced short palindromic repeats screencolorectal neoplasiacommunity engagementconfirmatory efficacy trialconfirmatory trialdevelopmentaldrivingengagement with communitiesengineered T cellsenrollepigeneticallyfirst in manfirst-in-humangenetically engineered T-cellsglioblastoma multiformegraft versus host diseasegraft vs host diseasegraft vs. host diseasehsp70 Familyimagingimmune check point inhibitorimmune drugsimmune evasiveimmune modulationimmune regulationimmune suppressionimmune suppressive activityimmune suppressive functionimmune system toleranceimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune unresponsivenessimmune-based cancer therapiesimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmune-mediated adverse eventsimmune-oncologyimmune-related adverse effectimmune-related adverse eventsimmune-related adverse reactionimmuno oncologyimmuno therapyimmunologic reactivity controlimmunologic therapeuticsimmunological paralysisimmunology oncologyimmunomodulatoryimmunoregulationimmunoregulatoryimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimmunotherapeuticsimmunotherapy agentimmunotherapy for cancerimmunotherapy of cancerin situ vaccineindividualized cancer careindividualized oncologyinhibitorlarge bowel neoplasmlung cancermRNA vaccinemRNA-based vaccinemalignancymanufacturemedical collegemedical schoolsmeetingmeetingsmembermicrobial consortiamicrobial floramicrobiotamicrofloramicrofluidic chipmicrotubule associated protein 2 kinasemitochondrialmonocytemultidisciplinarymultispecies consortianeoplasm/cancerneoplastic cellneuro-oncologyneurooncologynoveloncoimmunologyoncology clinical trialoncology programoncolytic adenoviruspathophysiologypathwaypembrolizumabpersonalized oncologyplasmocytepolymerpolymericpotency testingpre-clinical testingprecision cancer careprecision cancer medicineprecision oncologypreventpreventingprogenitor cell based therapyprogenitor cell therapyprogenitor cell treatmentprogenitor therapyprogenitor transplantationprogenitor treatmentprogrammed cell death 1programmed cell death ligand 1programmed cell death protein 1programmed cell death protein ligand 1programmed death 1programsprotein death-ligand 1protein kinase IIrecruitresistantschool of medicinesignaling lymphocytic activation moleculesignaling lympocyte activation moleculesle2small moleculesocial rolespongioblastoma multiformestem and progenitor cell therapystem and progenitor cell transplantationsstem cell based therapystem cell mediated therapystem cell therapeuticsstem cell therapystem cell treatmentstem cell-based therapeuticstem cell-based treatmentsystemic lupus erythematosus susceptibility 2thymus derived lymphocytetransgenic T- cellstranslationtranslation researchtranslational investigationtumortumor infiltrating T cellstumor microenvironmentunder representation of groupsunder represented groupsunder represented peopleunder represented populationsunderrepresentation of groupsunderrepresented peoplevaccine for cancervectorαPD-1αPD1β-catenin
Description preview
The Immuno-Oncology Program (IO) established in 2021 unites basic, translational and clinical research scientists from the various disease site programs to address the urgent need to discover novel cancer immunobiologic processes that can be exploited to develop safer, more effective immunotherapies for cancer patients. Through targeted…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click